Colony Group’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $725K | Sell |
7,121
-368
| -5% | -$37.4K | 0.01% | 486 |
|
|
2023
Q2 | $756K | Sell |
7,489
-85
| -1% | -$8.5K | 0.01% | 487 |
|
|
2023
Q1 | $697K | Sell |
7,574
-1,422
| -16% | -$124K | 0.01% | 506 |
|
|
2022
Q4 | $816K | Buy |
8,996
+1,795
| +25% | +$151K | 0.01% | 526 |
|
|
2022
Q3 | $547K | Buy |
7,201
+4,617
| +179% | +$383K | 0.01% | 558 |
|
|
2022
Q2 | $218K | Sell |
2,584
-4,768
| -65% | -$418K | ﹤0.01% | 763 |
|
|
2022
Q1 | $645K | Buy |
7,352
+118
| +2% | +$10.2K | 0.01% | 573 |
|
|
2021
Q4 | $633K | Buy |
7,234
+2
| +0% | +$166 | 0.01% | 537 |
|
|
2021
Q3 | $591K | Sell |
7,232
-1,126
| -13% | -$101K | 0.01% | 543 |
|
|
2021
Q2 | $763K | Sell |
8,358
-2,226
| -21% | -$198K | 0.02% | 436 |
|
|
2021
Q1 | $905K | Buy |
10,584
+1,925
| +22% | +$173K | 0.02% | 418 |
|
|
2020
Q4 | $818K | Sell |
8,659
-1,873
| -18% | -$164K | 0.02% | 407 |
|
|
2020
Q3 | $916K | Buy |
10,532
+265
| +3% | +$23K | 0.02% | 370 |
|
|
2020
Q2 | $897K | Sell |
10,267
-356
| -3% | -$30.7K | 0.03% | 360 |
|
|
2020
Q1 | $876K | Buy |
10,623
+1,498
| +16% | +$134K | 0.03% | 357 |
|
|
2019
Q4 | $864K | Sell |
9,125
-1,078
| -11% | -$96.7K | 0.02% | 433 |
|
|
2019
Q3 | $887K | Buy |
10,203
+81
| +0.8% | +$7.27K | 0.03% | 392 |
|
|
2019
Q2 | $924K | Buy |
10,122
+4,397
| +77% | +$372K | 0.03% | 394 |
|
|
2019
Q1 | $493K | Buy |
5,725
+2,145
| +60% | +$172K | 0.02% | 401 |
|
|
2018
Q4 | $275K | Sell |
3,580
-139
| -4% | -$10.8K | 0.01% | 416 |
|
|
2018
Q3 | $287K | Buy |
3,719
+196
| +6% | +$14.5K | 0.01% | 421 |
|
|
2018
Q2 | $238K | Sell |
3,523
-134
| -4% | -$9.25K | 0.01% | 445 |
|
|
2018
Q1 | $265K | Sell |
3,657
-4,686
| -56% | -$357K | 0.01% | 420 |
|
|
2017
Q4 | $628K | Buy |
8,343
+5,405
| +184% | +$408K | 0.04% | 284 |
|
|
2017
Q3 | $226K | Sell |
2,938
-62
| -2% | -$4.68K | 0.02% | 405 |
|
|
2017
Q2 | $224K | Buy |
+3,000
| New | +$213K | 0.02% | 392 |
|
|
2016
Q1 | – | Sell |
-6,673
| Closed | -$514K | – | 500 |
|
|
2015
Q4 | $514K | Sell |
6,673
-29
| -0.4% | -$2.3K | 0.05% | 251 |
|
|
2015
Q3 | $552K | Sell |
6,702
-400
| -6% | -$35.6K | 0.06% | 231 |
|
|
2015
Q2 | $626K | Buy |
7,102
+7,014
| +7,970% | +$643K | 0.07% | 239 |
|
|
2015
Q1 | $8K | Sell |
88
-2,679
| -97% | -$238K | ﹤0.01% | 597 |
|
|
2014
Q4 | $230K | Buy |
2,767
+2,444
| +757% | +$203K | 0.02% | 317 |
|
|
2014
Q3 | $27K | Hold |
323
| – | – | ﹤0.01% | 490 |
|
|
2014
Q2 | $26K | Hold |
323
| – | – | ﹤0.01% | 400 |
|
|
2014
Q1 | $25K | Hold |
323
| – | – | ﹤0.01% | 412 |
|
|
2013
Q4 | $23K | Buy |
+323
| New | +$22.5K | ﹤0.01% | 386 |
|
Other funds holding NVS
Colony Group's NVS Position: Q3 2023 in Review
Colony Group reduced its Novartis (NVS) stake by 4.9% in Q3 2023, selling an estimated $37.4K and leaving 7,121 shares worth $725K. The position accounts for 0.01% of the portfolio, ranked #486.
Colony Group first reported a position in NVS in Q4 2013 and has held it in 35 quarters since. The position peaked at $924K in Q2 2019. 1,224 funds tracked by Wall St. Rank hold NVS as of Q3 2023.
- Colony Group held 7,121 shares of Novartis worth $725K as of Q3 2023.
- Colony Group sold 368 Novartis shares in Q3 2023, an estimated $37.4K.
- Novartis made up 0.01% of Colony Group's portfolio in Q3 2023, its #486 holding.
- Colony Group first reported a position in Novartis in Q4 2013 and has held it in 35 quarters since.
- Colony Group's Novartis position peaked at $924K in Q2 2019.
- 1,224 funds tracked by Wall St. Rank held Novartis as of Q3 2023.
Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.